Last reviewed · How we verify
NCT04794608: Hyp_Hem
Hypnosis in Virtual Reality in Patients in Protector Isolation Room for Aplasia in Clinical Hematology.
NA trial testing HYPNO VR® device in Aplasia in 60 participants. Completed in 28 February 2024.
30 January 2024
Quick facts
| Lead sponsor | Hôpital Privé Sévigné |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 60 |
| Start date | 17 June 2021 |
| Primary completion | 30 January 2024 |
| Estimated completion | 28 February 2024 |
| Sites | 1 location across France |
Drugs / interventions tested
- HYPNO VR® device
Conditions studied
- Aplasia — all drugs for Aplasia →
Sponsor
Hôpital Privé Sévigné — full company profile →
Who can join
18 and older, any sex, with Aplasia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Hematology patients are frequently treated in hospital for aplasia. Patients are then placed in protective isolation room. This situation of protective isolation can represent a significant source of stress and anxiety for the patient. Hypnosis is already used to treat anxiety in patients with cancer. The purpose of this study is to evaluate the impact of virtual reality medical hypnosis sessions on anxiety and chronic pain of patients hospitalized for aplasia in order to broaden the supportive care proposals in the clinical hematology service of Sévigné Private Hospital.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04794608
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of HYPNO VR® device
Trials testing the same drug.
- NCT04533958 — Evaluation of Hypnosis in Virtual Reality on the Anxiety of Patients With Metastatic Prostate Cancer Over Chemotherapy · NA · completed
Other recruiting trials for Aplasia
Currently open trials in the same condition.
- NCT05790733 — HYPNONAG : Therapeutic Communication Versus Traditional Method for Naso-gastric Intubation in Haematology · NA · recruiting
Other Hôpital Privé Sévigné trials
Trials by the same sponsor.
- NCT06832995 — Incidence and Risk Factors for Post-Anesthetic Morphine Titration in Recovery Room After Hip and Knee Arthroplasties · active not recruiting
- NCT04112277 — Observational Prospective Study of Opiate-free Anesthesia for Anterior Total Hip Replacement · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04794608 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hôpital Privé Sévigné
- Last refreshed: 6 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04794608.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing